Cardilin T, Almquist J, Jirstrand M, Zimmermann A, Lignet F, El Bawab S, et al. Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents. Cancer Chemother Pharm. 2019;83:1159–73.

Article  CAS  Google Scholar 

Checkley S, MacCallum L, Yates J, Jasper P, Luo H, Tolsma J, et al. Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738. Sci Rep. 2015;5. https://doi.org/10.1038/srep13545.

Fernandez E, Mistry H, Brightman FA, Orrell D, Generali DG, Milani M. et al. From preclinical to phase II: using virtual tumor clinical model to predict the efficacy of randomised phase II trials. J Clin Oncol. 2015;33:e12032

Article  Google Scholar 

Fernandez E, Orrell D, Brightman F, Fell D, Chassagnole C. Modeling ionizing radiation exposure in vitro and in vivo using the Virtual Tumour. Cancer Res. 2013;73:5233–5233.

Article  Google Scholar 

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharm. 2012;1:e6.

Article  CAS  Google Scholar 

Ortega F, Brightman FA, Chassagnole C. Abstract LB-392: Optimizing dual immuno-oncology combinations with a virtual tumor. In: Bioinformatics, convergence science, and systems biology. American Association for Cancer Research; 2020. p. LB-392.

Ortega FG, Brightman FA, Orell D, Mistry H, Millen J, Chassagnole C. Abstract 680: Predicting the effect of radiotherapy on tumor growth inhibition and time to progression in head and neck cancer. In: Bioinformatics, convergence science, and systems biology. American Association for Cancer Research; 2019. p. 680.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

Article  CAS  PubMed  Google Scholar 

Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.

Article  PubMed  PubMed Central  Google Scholar 

Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362ps17.

Article  PubMed  Google Scholar 

Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

Article  CAS  PubMed  Google Scholar 

Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl J Med. 2016;375:2154–64.

Article  CAS  PubMed  Google Scholar 

Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40:3952–64.

Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505.

Article  CAS  PubMed  Google Scholar 

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48.

Article  CAS  PubMed  Google Scholar 

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.

Article  CAS  PubMed  Google Scholar 

Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606–22.

Article  CAS  PubMed  Google Scholar 

Pilie P, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA mutant cancers. Clin Cancer Res. 2019;25:3759–71.

Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66:801–17.

Article  CAS  PubMed  Google Scholar 

Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol OncolJ Hematol Oncol. 2019;12. https://doi.org/10.1186/s13045-019-0733-6.

Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharm Ther. 2015;149:124–38.

Article  CAS  Google Scholar 

Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res. 2017;23:3097–108.

Article  CAS  PubMed  Google Scholar 

Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19:26–38.

Article  CAS  PubMed  Google Scholar 

Wilson Z, Odedra R, Wallez Y, Wijnhoven PWG, Hughes AM, Gerrard J, et al. ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res. 2022;82:1140–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tutt A, Nowecki Z, Szoszkiewicz R, Im S-A, Arkenau H-T, Armstrong A, et al. 161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2022;33:S194–S195.

Article  Google Scholar 

Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, et al. Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163:246–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wethington SL, Shah PD, Martin LP, Tanyi JL, Latif NA, Morgan MA, et al. Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. J Clin Oncol. 2021;39:5516–5516.

Article  Google Scholar 

Jo U, Senatorov IS, Zimmermann A, Saha LK, Murai Y, Kim SH, et al. Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents. Mol Cancer Ther. 2021;20:1431–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turchick A, Zimmermann A, Chiu L-Y, Dahmen H, Elenbaas B, Zenke FT, et al. Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergis